Loading
Nimotuzumab is a Cuban-developed antibody against EGFR approved in India, China, Cuba and other countries for head and neck cancer, nasopharyngeal cancer and brain tumours, usually with radiotherapy; it causes far less rash than cetuximab but has never been approved in the United States or Europe.
Nimotuzumab was developed at Cuba's Center of Molecular Immunology and is marketed through partners in India (BIOMAb EGFR), China (Taixinsheng), Cuba and more than 25 other countries. Approvals cover squamous cell carcinoma of the head and neck with radiotherapy or chemoradiotherapy, nasopharyngeal carcinoma, high-grade glioma in children and adults, and in some countries oesophageal and pancreatic cancer. Its intermediate affinity means bivalent binding only on cells with dense EGFR, which gives it a milder toxicity profile than cetuximab. Randomised trials from India and China show improved locoregional control and survival with chemoradiotherapy in head and neck cancer, but the drug has not been submitted to the FDA or EMA.
Binds the extracellular domain of EGFR with moderate affinity, so it accumulates mainly on cells with high receptor density and spares normal skin, which explains its mild rash. Connects to EGFR.
1.Nimotuzumab binds EGFR.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Nimotuzumab" OR ABSTRACT:"Nimotuzumab" OR TITLE:"BIOMAb EGFR" OR ABSTRACT:"BIOMAb EGFR" OR TITLE:"TheraCIM" OR ABSTRACT:"TheraCIM" OR TITLE:"CIMAher" OR ABSTRACT:"CIMAher" OR TITLE:"h-R3" OR ABSTRACT:"h-R3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Nimotuzumab, not a curated reading list.
Shares Oesophageal cancer, Head and neck squamous cell carcinoma and the tag chembl-universe.
Shares EGFR and the tag chembl-universe.
Shares Oesophageal cancer and the tag chembl-universe.
Shares Pancreatic ductal adenocarcinoma and the tag chembl-universe.
Shares AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer, HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients, Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer, KRAS wild-type pancreatic ductal adenocarcinoma.
Shares A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer, Oesophageal cancer, Head and neck squamous cell carcinoma.
Shares Cetuximab, EGFR, Pancreatic ductal adenocarcinoma.